提供支持According to VCBeat, Yueying Technology has completed of tens of millions of yuan in Series A financing. The investors have not been disclosed. The funds will be used for clinical trials and new product development.
Yueying Technology is committed to the R&D of imaging diagnosis and treatment of heart and brain diseases. Its CT-FFR technology makes the diagnosis of coronary heart disease from invasive to non-invasive, so as to make the diagnosis of coronary heart disease more convenient and accurate.
Based on an expert team and graphics modeling, artificial intelligence, automatic hemodynamic simulation, and other technologies, Yueying Technology develops rapidly, and the latest CT-FFR technology product “Maiying” has been launched.
“Maiying” passed the national inspection report and has been used in some third-class hospitals. In terms of product promotion, Zhang Chao said, “‘Maiying’ has different modules, such as morphological post-processing, functional judgment, and data mining. By splitting these modules, ‘Maiying’ provides flexible and customized services to cardiologists in the form of offline workstations and software modules.”
"Our team's image processing technology solves the problem of inaccurate angiography modeling, reduces the error of image information and improves the diagnostic value of CT angiography," the founder Zhang Chao said.
The company's automatic hemodynamic simulation technology is not limited to the application of “Maiying”, but also can be used in other products. For example, Yueying Technology independently developed FFRDSA technology based on DSA imaging technology, which has entered the pre-experimental stage.
Currently, Yueying Technology is engaged in the B round of financing. Meanwhile, the company is also seeking cooperation with hospitals and medical device manufacturers to integrate ‘Maiying’ and other related products into the clinical diagnosis process and promote the implementation of medical imaging technology.
渝公网安备 50011202502165号
